+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      UV-B-lnduced Cataract Model in Brown-Norway Rat Eyes Combined with Preadministration of Buthionine Sulfoximine

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In order to develop a more adequate ultraviolet (UV)-induced cataract model, a combination of /-buthionine sulfoximine (BSO) treatment was applied to experimental animals. A single administration of BSO 4 mmol/ kg caused reduced glutathione concentration until experimental day 8. In the 0.067-J/cm<sup>2</sup> UV-B irradiation experiment, the light-scattering intensity of the anterior lens cortex of the combination group was significantly higher than that of the other groups during the second week after irradiation commenced. After the fourth experimental week, however, there was no significant difference between the group treated by UV-B alone and the combination group. In the 0.2-J/cm<sup>2</sup> UV-B irradiation experiment, anterior polar cataract was seen in the group receiving UV-B alone, as already reported, 6 weeks after starting UV irradiation. Meanwhile, in the combination group, shallow cortical opacity was seen at 26 weeks after the start of experiment in the deeper lenticular layer which was separated from the anterior subcapsular opacity. This anterior shallow cortical opacity seemed to move towards the nuclear region during the time course of the experiment. The results of this experiment suggested that the BSO treatment accelerated cataractogenesis through additional UV-B irradiation. Although more experiments are needed, this model is useful in investigating the connection between UV-B and other cocataractogenic factors in age-related cataract in humans.

          Related collections

          Author and article information

          Ophthalmic Res
          Ophthalmic Research
          S. Karger AG
          11 December 2009
          : 28
          : Suppl 2
          : 54-63
          Department of Ophthalmology, Kanazawa Medical University, Uchinada, Japan
          267957 Ophthalmic Res 1996;28:54–63
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10


          Comment on this article